Hospitalized Patients with Community-Acquired Pneumonia in Hong Kong: A Randomized Study Comparing Imipenem/Cilastatin and Ceftazidime

Respiration

Volumn 64, Issue 3, 1997, Pages 224-228

  Ho, Alice ^a   Leung, Roland ^a   Lai, Christopher K W ^a   Chan, Tak Hin ^a   Chan, Christopher H S ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNITED CHRISTIAN HOSPITAL   (Hong Kong)

Author keywords

Ceftazidime; Community acquired pneumonia; Imipenem cilastatin

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CLOXACILLIN; ERYTHROMYCIN; TUBERCULOSTATIC AGENT; VANCOMYCIN;

ADULT; AGED; ARTICLE; BRONCHOSCOPY; CHLAMYDIACEAE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DYSPNEA; FEMALE; HONG KONG; HOSPITAL PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; SPUTUM; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0030887116     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000196675     Document Type: Article

References (12)

1. American Thoracic Society: Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Rcspir Dis 1993:148:1418-1426.
2. Chan CHS. Cohen M. Pang J: A prospective study of community-acquired pneumonia in Hong Kong. Chest 1992:101:442-446.
3. Lam WK. Chan PY. So SY. Leung YK. Chan JCK. Ip M. Sham MK: Ofloxacin compared with amoxycillin in treating infective exacerbations in bronchiectasis. Rcspir Med 1989:83: 299-303.
4. Fang GD. Fine M. Orlol TJ. Arisumi D. Yu VL. Kapoor W. Grayston JT. Wang SP. Kohler R. Muder RR. Yee YC. Rihs JD. Vickers RM: New and emerging aetiologies for community-acquired pneumonia with implications for therapy: A prospective multicentre study of 359 cases. Medicine 1990:69:307-316.
5. Pachon J, Prados MD, Capote F, Cuello JA, Gamacho J, Verano A: Severe community-acquired pneumonia. Etiology, prognosis and treatment. Am Rev Respir Dis 1990; 142:369-373.
6. MacFarlanc JT. Word MJ. Finch RG. MaCrac AD: Hospital study of adult community-acquired pneumonia. Lancet 1982:2:255-258.
7. Burman LA, Trollfors B, Anderson B, Hcn-richsen J, Juto P, Kallings I, Lagergard T, Mollbv R, Norrby R: Diagnosis of pneumonia by culture, bacterial and viral antigen detection tests, and serology with special reference to antibodies against pneumococcal antigens. J Infect Dis 1991:163:1087-1093.
8. Lam WK, Chau PY, Chan JCK, Ip MSM: Ofloxacin vs ccfuroximc in the treatment of lower respiratory infections in moderately immunocompromised patients. Drugs 1993: 45(suppl 3):416-417.
9. Pang JA, Cheng A, Chan HS, Poon D, French G: The bacteriology of bronchiectasis in Hong Kong investigated by protected catheter brush and bronchoalvcolar lavage. Am Rev Respir Dis 1989:139:14-17.
10. British Thoracic Society: The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit. Respir Med 1992:86:7-13.
11. Hosker HSR. Tam JS. Chan CHS. Lai CKW: Mycoplasma pneumoniae infection in Hong Kong-clinical and epidemiological features during an epidemic. J Infect 1980:2:191-194.
12. Calandra GB. Wang C. Aziz M. Brown KR: The safety profile of imipenem/cilastatin: Worldwide clinical experience based on 3.470 patients. J Antimicrob Chcmothcr 1986; 18(suppl E): 193-202.